News
Inhibit cell death to save the myocardium and the patient's life during a heart attack
Roca Therapeutics was created in Nice in 2021. The company comes from the work of four researchers from the Nice Cancer and Aging Research Institute (IRCAN) and the Nice Chemistry Institute (ICN), who have worked for more than 10 years to understand the mechanisms of resistance to treatments in cancers, and more precisely in a very aggressive cancer, uveal melanoma (eye cancer). From their research, a patented molecule, RCT001, was born in 2019, then the biotech Roca Therapeutics in 2021.
Émilie Royère is the general director of Eurobiomed, ...
Since 2010, immunotherapy, a therapy based on the immune system, has experienced considerable growth. The main innovation lies in the therapeutic possibilities (drugs) as well as the progressive understanding of the mechanisms.
"Marseille Immunology Biocluster" (MIB) est officiellement lancé aujourd’hui. Labellisée "France 2030", la structure sera dotée de 96 millions d’euros sur 10 ans. Objectif de ce projet, dont "La Provence" a obtenu les détails : mobiliser la filière, déjà solidement ancrée dans la région, pour mettre au point des traitements innovants pour de nombreuses maladies.
Created in 2022 and based in Marseille, Ana Healthcare's mission is to accelerate medical research by simplifying the analysis of medical imaging data.
Created in Toulouse in 2017, Sêmeia develops simple, intuitive and effective support solutions for patients suffering from serious or chronic illnesses.
A specialist in respiratory diseases, the RespirERA university hospital institute (IHU), based in Nice, wants to prevent the ailments that atmospheric pollution and climate change will transform into a major public health problem tomorrow.
Inhibit cell death to save the myocardium and...
Created in 2013 and based in Grabels (34) and Labège (31), ...
The Max Delbrück Center, Berlin, and the biotech company AlgenScribe from France have agreed to cooperate to further develop their gene-editing tools. The aim is to utilize synergies, accelerate research, and ultimately develop cell therapies for genetically determined diseases.
Created in Toulouse in 2005, ABIONYX Pharma is a ...